Antigenics Oncophage Retrospective Testing For Potency Is Approval Issue
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Approval of Antigenics’ Phase III cancer vaccine Oncophage rests on whether FDA will accept retrospective testing of vaccine used in pivotal trials to support product characterization, the company said.